Drug Target Review

APRIL 9, 2024

For his postdoctoral stay he joined the group of André Nussenzweig, where he started to work on DNA repair, particularly focusing on the role of histone H2AX. Among other discoveries, the group developed inhibitors of the ATR kinase and showed their potential for cancer therapy.

RNA 64

RNA Cell Biology Clinical Development Disease 64

Conversations in Drug Development Trends

JULY 8, 2024

With radiopharmaceuticals emerging as a diagnostic and therapeutic (theranostics) procedure, many are in the clinical development pipeline and are expected to play a crucial role in the future of healthcare. Genetic Factors : Certain genetic mutations, such as those in DNA repair genes, can affect how cells respond to radiation.

Clinical Trials 52

Clinical Trials Regulations Therapies Clinical Development 52

Drug Target Review

SEPTEMBER 10, 2024

The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. Hence, in many cases an earlier IND may be prevented by the timely provision of representative Drug Substance (DS) to execute such toxicology studies.

Drug Development 64

Drug Development Clinical Supply Production Protein Expression 64

The Pharma Data

OCTOBER 19, 2020

Caris Precision Oncology Alliance members also have access to the Caris Pharmatech oncology trial network, which can help reduce the time it takes to identify and connect appropriate patients with novel targeted cancer therapies in clinical development.

Clinical Trials 52

Clinical Trials RNA DNA Science 52

The Pharma Data

JUNE 28, 2021

Bayer’s acquisition of Noria and PSMA Therapeutics, which have nurtured Dr. Babich’s radiopharmaceutical and diagnostic technology, is an important milestone in drug development, and we look forward to the advances this collaboration can make to enhance prostate cancer therapies.”.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

Agency IQ

APRIL 12, 2024

In drug development, biochemical assays might be used to determine a product’s binding affinity to a target receptor of interest, along with the strength, stability and duration of the target-ligand complex after the product binds to the receptor. The new draft guidance can be broken into three main parts.

Production 40

Production FDA Therapies Biochemical Assays 40

Drug Target Review

JANUARY 15, 2024

Unlike almost every other cell type (except B cells), T cells do not have the exact same chromosomal DNA sequences as other cells in the body. In previous decades, isolation, sequencing and characterisation of DNA encoding a specific TCR was laborious and technically challenging. References Robinson R, McMurran C, McCully M, Cole D.

Engineering 110

Engineering DNA Virus Immune Response 110

Advarra

AUGUST 10, 2023

Given the relatively small populations affected by any one rare disease or condition, a pharmaceutical company developing an orphan drug may reasonably expect the final approved drug to generate relatively small sales (when compared with the drug development costs) and consequently incur a financial loss.

Drug Development 52

Drug Development Disease Therapies Engineering 52

Broad Institute

OCTOBER 11, 2023

Calico, together with AbbVie, has worked with TIDE to advance some of its drug discovery and development programs and now has projects — including the PTPN2 inhibitors — in various stages of preclinical and clinical development.

Research 137

Research Immune Response Clinical Trials Therapies 137

Drug Target Review

JULY 18, 2024

Why is detecting cancers via liquid biopsy before they become visible on imaging important for drug development, not just diagnostics? We believe liquid biopsy is very helpful for oncology drug development because the reduction and clearance of circulating DNA occurs quickly before radiographic imaging is available.

Drug Development 59

Drug Development Clinical Trials Drugs Vaccine 59

The Pharma Data

NOVEMBER 29, 2020

Compared to placebo, participants vaccinated with three HB-101 doses had: a 48 percent reduction in CMV viremia (presence of CMV DNA in the blood); a 42 percent reduction in the use of antiviral therapy; and. no CMV disease (compared to 2 out of 14 cases in the placebo group).

Vaccine 40

Vaccine Clinical Trials Disease Therapies 40

Agency IQ

FEBRUARY 2, 2024

EMA finalizes clinical anticancer therapeutic guidance update In a newly finalized revision, the EMA’s guideline covering all aspects of clinical development of anticancer therapeutics has expanded its already broad scope. The EMA started providing guidance on the clinical development of anticancer therapeutics in 1996.

Clinical Trials 40

Clinical Trials Trials Treatment Disease 40

Drug Target Review

DECEMBER 13, 2024

7,8 The discovery of these biomarkers provides valuable insights into prognosis and disease progression, while also guiding the clinical development of new targeted immunotherapies. 7 Recent clinical studies highlight promising developments in c-MET-targeting ADCs for NSCLC. Phuna ZX, Kumar PA, Haroun E, Dutta D, Lim SH.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

The Pharma Data

OCTOBER 26, 2020

The increase was primarily driven by higher expenses related to clinical development and increased investment in discovery research and early drug development, partially offset by lower laboratory, travel and meeting expenses due to the COVID-19 pandemic. Organon & Co. Non-GAAP R&D expenses were $2.3

Vaccine 40

Vaccine Trials Treatment Virus 40

LifeSciVC

FEBRUARY 5, 2025

Transcription factors are well-known entities they are the hairclip-shaped molecules that when activated, travel into to the nucleus, grab onto DNA, and drive the transcription of genes into proteins.

Small Molecule 68

Small Molecule Targeted Protein Degradation Regulations Disease 68

BioPharma Drive: Drug Pricing

JUNE 9, 2025

However, with this kind of promise comes more scientific, ethical and financial questions that healthcare providers and drug development professionals must seriously consider. As more people take them and their uses grow, so does their potential. Its new CEO has to figure out what’s next.

Clinical Trials 144

Clinical Trials Drugs Therapies Clinical Supply 144

BioPharma Drive: Drug Pricing

JUNE 5, 2025

These are exactly the applications where current generative AI … completely excels and where we see similar gains in drug development and scientific review internally at Lantern Pharma,” he said. Bloomberg 23andMe’s DNA Data Gets Boosted $305 Million Bid in New Auction View all Events 17 JUN Webinar | 10:30 a.m.

FDA 130

FDA Therapies Clinical Supply Licensing 130

Drug Target Review

MAY 27, 2025

I sequenced the complementary DNA (cDNA) encoding RAS GTPase Activating Protein, a protein known that regulates cell growth, differentiation and survival of cells; mutations in these proteins are linked to cancer. My proudest achievement is my leadership journey building legacy organisations, processes and tools in clinical operations.

Clinical Trials 52

Clinical Trials Molecular Biology Trials Clinical Supply 52

BioPharma Drive: Drug Pricing

JUNE 11, 2025

billion buyout of Blueprint Medicines is the sector’s second-largest M&A deal this year and represents the highest value paid for an immune drug developer since April 2023. Sanofi’s $9.1 Sanofi’s $9.1

FDA 167

FDA Drugs Therapies Science 167